TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03600311

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Post-Exercise Carbohydrate
Description: Participants will ingest 30 g of carbohydrate following exercise.
Study: NCT04304014

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. longum and P. Pentosaceus
Description: (10\^9 CFU) once a day
Study: NCT01323244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
Study: NCT03249805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Steenbeek Foot Abduction Brace (SFAB)
Description: The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiracleFeet Foot Abduction Brace (mFAB)
Description: Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
Study: NCT05840536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Patients will receive furosemide infusion at 5mg/hr along with an initial bolus dose of furosemide equal to twice their home oral dose. The furosemide infusion can be increased to 10mg/hr after 12hrs based on urine output. This arm will receive bolus doses of furosemide every 12hrs equal to twice their home oral dose until completion of the protocol.
Study: NCT02870530

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Anastomosis Sleeve Jejunal (SAS-J) Bypass
Description: Single Anastomosis Sleeve Jejunal (SAS-J) Bypass as A treatment for Morbid
Study: NCT02635399

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: PPPD (pylorus-preserving pancreaticoduodenectomy)
Description: pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
Study: NCT02228850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprostadil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04578535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HYQVIA
Description: Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Study: NCT03556020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemziviptadil (PB1046)
Description: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemziviptadil (PB1046)
Description: Pemziviptadil (PB1046), Once Weekly Subcutaneous Injection
Study: NCT03317119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine and Tipiracil Hydrochloride
Description: Given PO
Study: NCT01699568

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RFA
Description: Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
Study: NCT02402413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Determination of concentrations of androgens
Description: Determination of concentrations of serum levels of circulating androgens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Three dimensional ultrasound probe
Description: Capture of ovarian three dimensional volumes
Study: NCT03341455

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Capacity building to support families affected by IPV & substance misuse
Description: Training targeted groups (mothers, fathers, preschool teachers, community officers managing preschools) separately with the aim to identify and support high-risk families early enough to arrest the cycle of violence that results in children themselves becoming victims and perpetrators of such violence.
Study: NCT02379468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pedyphar Ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panthenol
Description: Ointment
Study: NCT03087292

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training with vascular occlusion
Description: Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
Study: NCT04416906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biktarvy
Description: Once daily fixed dose combination regimen of Biktarvy will be evaluated as a rapid treatment strategy in newly HIV diagnosed patients HIV diagnosed patients that come for the first time to the Hospital Clínic HIV Unit
Study: NCT02317978

Intervention type: PROCEDURE
Intervention: ICSI
Description: records of women who had ICSI will be reviewed and analysed for determining FSI
Study: NCT01829022

Intervention type: PROCEDURE
Intervention: E-NOTES
Description: Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
Study: NCT01243827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP \<140/90 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bisoprolol
Description: bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP \<140/90 mmHg.
Study: NCT03394352

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity on Board
Description: During the collection phase, the study team will collect information on glucose values, activity measures and insulin settings. This information will be used to determine the meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the data collection phase and study admission.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Diabetes Care
Description: Subjects will perform their usual diabetes care including basal rate, meal and correction boluses during the study admission. Subjects will wear a continuous glucose monitor during the study admission.
Study: NCT02315482

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pneumoperitoneum insufflation and steep trendelenburg
Description: the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pneumoperitoneum insufflation and steep trendelenburg
Description: the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
Study: NCT04533867

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape

Intervention type: PROCEDURE
Intervention: Laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy, also called a vertical sleeve gastrectomy, is a surgical weight-loss procedure. This procedure is typically performed laparoscopically, which involves inserting small instruments through multiple small incisions in the upper abdomen. During sleeve gastrectomy, about 80 percent of the stomach is removed, leaving a tube-shaped stomach about the size and shape

Intervention type: DRUG
Intervention: Palonosetron 1mcg/kg
Description: Injectable Palonosetron 1 mcg/kg diluted up to 5 mL with normal saline solution and injected intravenously at the end of the bariatric surgery.
Study: NCT01885312

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Tailored Intervention
Description: Adaptive

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consequence-based Intervention
Description: Loss Framed
Study: NCT04533867

Intervention type: DRUG
Intervention: Ondansetron 1 mg/kg, max dose 8 mg
Description: Injectable ondansetron 0.1 mg/kg, maximum of 8 mg was injected intravenously at the end of the bariatric surgery.
Study: NCT03088813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: IV
Study: NCT03600311

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D
Description: Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium and Vitamin D
Description: Participants will be supplied Calcium and Vitamin D supplements throughout the study period matched to the CON condition.
Study: NCT05170516

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4 °C colled saline irrigation
Description: In Experimental Group A , 4 °C colled saline irrigation was used during impacted third molar surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 10 °C cooled saline irrigation
Description: Experimental Group B, 10°C colled saline irrigation was used during impacted third molar surgery.
Study: NCT01885312

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tailored, not adaptive, based Intervention
Description: Baseline tailored not adaptive

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment only
Description: EMA only
Study: NCT03088813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome injection
Description: IV
Study: NCT02724904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
Study: NCT05170516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature saline irrigation
Description: In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Room temperature saline irrigation
Description: In Control Group A and B, salin irrigation at room temperature was used during impacted third molar surgery.
Study: NCT00498784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirena
Description: Mirena 52mg during 1 year
Study: NCT00668876

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oral IMPACT
Description: postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral nutrition
Description: Parenteral nutrition
Study: NCT03575975

Intervention type: DEVICE
Intervention: Total Ankle Replacement Prosthesis
Description: Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.

Intervention type: DEVICE
Intervention: Total Ankle Replacement Prosthesis
Description: Comparison of functional range of motion in users of Stryker Scandinavian Total Ankle Replacement (STAR) prosthesis to users of INBONE 2 Total Ankle Replacement prosthesis and to matched controls with intact ankle joints.
Study: NCT03479424

Intervention type: OTHER
Intervention: Observational
Description: The MYIA in-home suite of devices.

Intervention type: OTHER
Intervention: Observational
Description: The MYIA in-home suite of devices.
Study: NCT03061617

Intervention type: OTHER
Group type: OTHER
Intervention: VCV mode
Description: set fixed 6ml/kg tide volume

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCV mode
Description: adjust pressure to achieve tide volume of 6ml/kg
Study: NCT03066687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Erdafitinib 9 mg (provided as one 4-mg tablet \[G-024\] and one 5-mg tablet \[G-025\]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
Study: NCT02635399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy
Description: pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
Study: NCT01443039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenotypical approach
Description: each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =\>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
Study: NCT04416074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: An online 5-week professional identity group psychotherapy
Description: This is an online 5-week group psychological intervention for the nursing students during clinical rotation practice. It aims at promoting the professional identity and career sefl-efficacy for them. There are five sessions in the intervention, and each session lasts from 60min to 90min at each week. The intervention will be delivered via an online meeting software, like Zoom. There will be 15-20 students in one meeting group.

Intervention type: OTHER
Group type: OTHER
Intervention: Message push
Description: Controlled group will receive online messages of self-care knowledge forward by researchers once per week. The knowledge contain stress regulation, strategies for relaxation, self-protection during clinical practice.
Study: NCT03328325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) IVR-186, B/Maryland/15/2016 NYMC BX-69A, (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Quadrivalent Inactivated Vaccine
Description: A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes: A/Singapore/GP1908/2015 (H1N1) IVR-180 (an A/Michigan/45/2015 \[H1N1\] pdm09-like virus), A/Singapore/INFIMH-16-0019/2016 (H3N2) NIB-104, B/Maryland/15/2016 NYMC BX-69A (a B/Colorado/06/2017-like virus), and B/Phuket/3073/2013.
Study: NCT00186121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole (Arimidex)
Description: Anastrozole is a prescription hormonal treatment that helps fight breast cancer by lowering the amount of estrogen in the body. It is a non-steroidal aromatase inhibitor, which significantly lowers serum estradiol (estrogen) concentrations, without interfering with the formation of adrenal corticosteroids or aldosterone
Study: NCT01826994

Intervention type: DEVICE
Group type: OTHER
Intervention: heart type fatty acid binding protein testing
Study: NCT01916109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical cystectomy
Study: NCT00636168

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ipilimumab
Description: IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
Study: NCT01622023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intra-uterine insemination
Description: Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-uterine insemination
Description: Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
Study: NCT04309578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab, Capecitabine and Cisplatin
Description: * Trastuzumab intravenous administration at a loading dose of 8 mg/kg on day 1 followed by 6 mg/kg every 3 weeks~* Capecitabine oral administration at a dose of 1000 mg/m2 twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)~* Cisplatin intravenous administration at a dose of 80 mg/m2 on day 1
Study: NCT04109651

Intervention type: OTHER
Group type: OTHER
Intervention: Nursing intervention
Description: Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Description: Nursing Intervention: This intervention was planned based on Meleis' Transition Theory. So it includes individual counseling and training.~In the Health Promotion Monitoring Program; three training modules and one reminder module were implemented and telephone counseling was provided. Various training tools were used in these trainings. Three different power point presentations were made during the training sessions. Illustrated printed training material was used. At the end of the training, training booklet was given to the participants.
Study: NCT00186121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex)
Description: Goserelin is a palliative treatment of advanced breast cancer in pre- and perimenopausal women
Study: NCT01998854

Intervention type: DEVICE
Intervention: VizAblate System
Description: The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids